Smith & Nephew Plc Stock

Equities

SN.

GB0009223206

Medical Equipment, Supplies & Distribution

Market Closed - London S.E. 11:35:19 2024-05-15 EDT 5-day change 1st Jan Change
1,020 GBX +0.20% Intraday chart for Smith & Nephew Plc +1.24% -5.42%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
Sales 2024 * 5.82B 7.91B Sales 2025 * 6.12B 8.33B Capitalization 11.27B 15.33B
Net income 2024 * 541M 736M Net income 2025 * 694M 944M EV / Sales 2024 * 2.38 x
Net Debt 2024 * 2.56B 3.48B Net Debt 2025 * 2.23B 3.03B EV / Sales 2025 * 2.21 x
P/E ratio 2024 *
21.9 x
P/E ratio 2025 *
16.8 x
Employees 18,452
Yield 2024 *
2.96%
Yield 2025 *
3.32%
Free-Float 99.15%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.20%
1 week+1.24%
Current month+4.19%
1 month+6.41%
3 months-8.03%
6 months-1.16%
Current year-5.42%
More quotes
1 week
998.40
Extreme 998.4
1 030.00
1 month
947.32
Extreme 947.3172
1 030.00
Current year
946.00
Extreme 946
1 181.50
1 year
887.00
Extreme 887
1 315.00
3 years
887.00
Extreme 887
1 601.50
5 years
887.00
Extreme 887
2 023.00
10 years
881.00
Extreme 881
2 023.00
More quotes
Managers TitleAgeSince
Chief Executive Officer - 22-03-31
Director of Finance/CFO 56 11-30
Compliance Officer - 99-03-31
Members of the board TitleAgeSince
Director/Board Member 65 17-09-30
Director/Board Member 62 23-09-13
Chairman 63 23-04-25
More insiders
Date Price Change Volume
24-05-15 1,020 +0.20% 2,323,465
24-05-14 1,018 +1.14% 1,875,429
24-05-13 1,006 +0.20% 1,376,439
24-05-10 1,004 +0.30% 1,966,596
24-05-09 1,002 -0.60% 1,764,796

Delayed Quote London S.E., May 15, 2024 at 11:35 am

More quotes
Smith & Nephew Plc specializes in designing, manufacturing and marketing medical products and equipment. Net sales break down by activity sector as follows: - orthopedic surgery (39.9%): primarily orthopedic implants (hips, knees and shoulders); - sports medicine, arthroscopy and cervicofacial surgery (31.2%): surgery and damaged tissue repair products and instruments, visualization products, etc.; - wound care (28.9%): skin grafts for major burns victims, treatments for leg ulcers, etc. The United States accounts for 53.7% of net sales.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
12.92 USD
Average target price
16.35 USD
Spread / Average Target
+26.49%
Consensus
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW